FRP Introduces New FX Series Designed for New and Experienced Riders 
Former Depop, Etsy and Missguided Marketing Leader Launches Specialist SEO and PPC Agency – VKNG Digital for Lancashire Businesses George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel…
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial
Press Release Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma…
Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)
Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary…
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new…
Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization…
Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
Bone Therapeutics secures up to €16 million loan financing from the European Investment Bank to accelerate ongoing clinical and commercial development of innovative orthopedic treatment
REGULATED INFORMATION The EIB financing to be used for Bone Therapeutics’ allogeneic cell therapy platform…
Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate
Saint-Herblain (France), July 1, 2021 – Following a media article published yesterday, Valneva SE, (Nasdaq:…
EXMceuticals Inc. Announces Resignation of Board Members
VANCOUVER, British Columbia, June 30, 2021 (GLOBE NEWSWIRE) — EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company”…
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”)…
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS)…
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”)…
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in…
Avicanna Financial Statement Update
TORONTO, June 30, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (the “Company” or “Avicanna”) (TSX: AVCN)…
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories…
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
The Company signed contracts for the manufacturing of registration batches in view of the potential…
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
PARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Nasdaq CM: BPTS,…
Ensysce Biosciences Announces Closing of Merger
Ensysce Common Stock to commence trading under ticker symbol “ENSC” on The Nasdaq Capital Market…
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing…